{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"33","value":"21.2"},{"groupId":"OG001","lowerLimit":"5","upperLimit":"14","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"DOR is defined as the time from documentation of a response to treatment to the first documentation of tumor progression or death due to any cause, whichever comes first.","dispersionType":"Full Range","groups":[{"description":"Participants with non-follicular iNHL with MZL as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.","id":"OG000","title":"MZL: Umbralisib"},{"description":"Participants with non-follicular iNHL with WM as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.","id":"OG001","title":"WM: Umbralisib"}],"paramType":"MEDIAN","populationDescription":"mITT population included all participants who received at least one dose of study treatment and provided at least some post baseline efficacy assessment. 'Overall number of participants analyzed' is the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"From the first demonstration of response to umbralisib till disease progression/death (up to approximately 4.2 years)","title":"Duration of Response (DOR)","type":"PRIMARY","unitOfMeasure":"months"}